738 related articles for article (PubMed ID: 25176136)
1. Ivabradine in stable coronary artery disease without clinical heart failure.
Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
[TBL] [Abstract][Full Text] [Related]
2. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
[TBL] [Abstract][Full Text] [Related]
3. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.
Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R
Am Heart J; 2013 Oct; 166(4):654-661.e6. PubMed ID: 24093844
[TBL] [Abstract][Full Text] [Related]
4. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
6. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study.
Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
Eur Heart J; 2015 Dec; 36(46):3291-6. PubMed ID: 26385957
[TBL] [Abstract][Full Text] [Related]
7. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
Cammarano C; Silva M; Comee M; Donovan JL; Malloy MJ
Clin Ther; 2016 Feb; 38(2):387-95. PubMed ID: 26839043
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice.
Perings S; Stöckl G; Kelm M;
Adv Ther; 2016 Sep; 33(9):1550-64. PubMed ID: 27432382
[TBL] [Abstract][Full Text] [Related]
10. Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention.
Werdan K; Ebelt H; Nuding S; Höpfner F; Stöckl G; Müller-Werdan U
Adv Ther; 2015 Feb; 32(2):120-37. PubMed ID: 25687888
[TBL] [Abstract][Full Text] [Related]
11. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the SIGNIFY trial.
Grassi G
Expert Opin Pharmacother; 2015; 16(12):1861-4. PubMed ID: 26153241
[TBL] [Abstract][Full Text] [Related]
13. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
Bruguera Cortada J; Varela A
Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
[TBL] [Abstract][Full Text] [Related]
14. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
15. Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.
Weeda ER; Nguyen E; White CM
Ann Pharmacother; 2016 Jun; 50(6):475-85. PubMed ID: 26917820
[TBL] [Abstract][Full Text] [Related]
16. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Perry CM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
[TBL] [Abstract][Full Text] [Related]
17. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study.
Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P
Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004
[TBL] [Abstract][Full Text] [Related]
18. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
[TBL] [Abstract][Full Text] [Related]
19. Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials.
Mengesha HG; Weldearegawi B; Petrucka P; Bekele T; Otieno MG; Hailu A
BMC Cardiovasc Disord; 2017 Apr; 17(1):105. PubMed ID: 28454527
[TBL] [Abstract][Full Text] [Related]
20. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]